Abstract
In the last 30 years, particle size reduction technologies turned from an exploratory approach into a mature commercial drug delivery platform. Nanonization technologies have gained a special importance due to a steadily increasing number of development compounds showing poor aqueo us so lubility. Many drug delivery companies and academic research groups have contributed to the currently existing large variety of different technol ogies to produce drug nanoparticles. These particles consist of pure active pharmaceutical ingredient (API) and are often stabilized with surfactants and/or polymeric stabilizers adsorbed onto their surface. The mean particle size ranges normally from 1 nm up to 1000 nm.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
